A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
Feature|Articles|August 6, 2026
Explicating the Status of ctDNA MRD Testing in the MIBC Treatment Paradigm
Author(s)Roman Fabbricatore
Fact checked by: Russ Conroy
Two bladder cancer specialists discussed how emerging ctDNA MRD testing advances will impact treatment selection for patients with MIBC.
Advertisement
Advertisement
The emergence of circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing, which non-invasively identifies microscopic cancer in the blood, has presented a new strategy to enhance the management of numerous cancerous malignancies.1 For bladder cancer, this testing may optimize risk stratification, inform postoperative decision-making processes, and introduce more personalized surveillance strategies for patients, particularly in treatment de-escalation.
Related to this article
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
Advertisement
Advertisement